UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* GOLDSTEIN DOV A MD					2. Issuer Name and Ticker or Trading Symbol NeuBase Therapeutics, Inc. [NBSE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/18/2021							Office	er (give title belo	ow)	Other (spe	cify belo	w)	
(Street) PITTSBURGH, PA 15219				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							uired, Disposed of, or Beneficially Owned						
(Instr. 3) Da			2. Transaction Date (Month/Day/Year	Exec any	Deemed cution Dat	Date, if	(Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D)	Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		Ownership Form:		Beneficial	
				(Mo:	nth/Day/Year)			Code V		Amour	(A) or (D)	Price	(Instr. 3 and 4)			\ /		Ownership (Instr. 4)
Common Stock 06/18/202			06/18/2021]	P		8,000	A	\$ 4.75	30,000			D (1)		
			Table II -					quire	the fo	orm dis	splays a of, or Ben	curre reficial	ntly valid	OMB con	spond unle trol numbe			
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/\)	Execution D Year) any	ate, if	4. Transaction Code (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Seco	ritle and ount of lerlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Own Forn Der Seco Dire or In	nership n of vative urity: ect (D) ndirect tr. 4)	Beneficia Ownersh (Instr. 4)	
					Code	V	(A)	(D)	Date Exerc	cisable	Expiration Date	n Title	or Number of Shares					
Repor	ting O	wners																

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
GOLDSTEIN DOV A MD C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR PITTSBURGH, PA 15219	X					

Signatures

/s/ Sam Backenroth, as attorney-in-fact for Dov A. Goldstein	06/21/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The power of attorney under which this form was signed is on file with the Commission.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.